Diagnostics developer Healthlinx Ltd hopes to have a multi-marker blood test for ovarian cancer on the market in the second quarter of calendar 2008, after successfully completing a Phase II bio-marker trial on its OvPlex test.A multi-marker test measures five substances in the blood, thereby increasing the likelihood of correctly diagnosing the presence of ovarian cancer and reducing the rate of misdiagnosis.A bio-marker is a specific biochemi